Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

69.2K
Overview
69.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

364
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
364
Tissue Transplantation01:24

Tissue Transplantation

417
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
417

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.

Bone marrow transplantation·2026
Same author

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Bone marrow transplantation·2026
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

The role of allogeneic stem cell transplantation in peripheral T-cell lymphoma.

Bone marrow transplantation·2026
Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026
Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jul 27, 2025

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

15.8K

Acute graft-versus-host disease.

Florent Malard1, Ernst Holler2, Brenda M Sandmaier3,4

  • 1Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. florent.malard@inserm.fr.

Nature Reviews. Disease Primers
|June 8, 2023
PubMed
Summary

Acute graft-versus-host disease (GVHD) is a serious complication following stem cell transplants. Current treatments like steroids and ruxolitinib are insufficient for refractory cases, highlighting an unmet medical need.

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.9K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.2K

Related Experiment Videos

Last Updated: Jul 27, 2025

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

15.8K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.9K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.2K

Area of Science:

  • Immunology
  • Hematology
  • Transplantation Medicine

Background:

  • Acute graft-versus-host disease (GVHD) is a frequent and severe immune complication after allogeneic haematopoietic cell transplantation (alloHCT).
  • GVHD significantly contributes to patient morbidity and mortality, posing a major health challenge.
  • It arises from donor immune cells attacking recipient tissues, primarily affecting the skin, gastrointestinal tract, and liver, typically within three months post-transplant.

Purpose of the Study:

  • To summarize the current understanding of acute GVHD pathophysiology, diagnosis, and treatment landscape.
  • To identify the limitations of existing therapies for acute GVHD.
  • To underscore the unmet medical need for effective treatments in steroid- and ruxolitinib-refractory acute GVHD.

Main Methods:

  • Review of existing literature on acute GVHD pathogenesis and clinical management.
  • Analysis of current treatment strategies, including prophylaxis and first- and second-line therapies.
  • Identification of gaps in treatment efficacy, particularly for refractory disease.

Main Results:

  • Acute GVHD is initiated by donor immune effector cells targeting recipient tissues.
  • Diagnosis relies on clinical presentation, supported by examinations to rule out other conditions.
  • Preventive strategies are standard, but not universally effective; steroids and ruxolitinib are used for treatment, but a significant proportion of patients develop refractory disease.

Conclusions:

  • Acute GVHD remains a critical challenge in alloHCT, associated with substantial risks.
  • Current therapeutic options, including steroids and ruxolitinib, do not adequately address all cases.
  • The lack of validated treatments for refractory acute GVHD represents a significant unmet medical need in the field.